Efficacy and Safety of Amantadine in Parkinson’s Disease with Dyskinesia and Motor Fluctuations: A Systematic Review and Meta-Analysis
Objective: To evaluate the efficacy and safety of oral amantadine (AMA) compared to placebo in the treatment of dyskinesia (DYS) and motor fluctuations (MF) in…Altered EEG Theta Activity Characterizes Parkinson’s disease with Levodopa-induced Dyskinesia
Objective: We explored the relationship between the build-up and the downscaling process in patients with Parkinson’s disease by analyzing theta frequency spectral bands. Background: During…Delta(0.5-2Hz) Spectral Power reduction in the frontal region in NREM Sleep are Associated with dyskinesia in Parkinson’s Disease
Objective: Our study aimed to establish the objective physiological indicators assessed by polysomnography(PSG) that are associated with dyskinesia in PD patients.Our study aimed to establish…Motor complications in Parkinson’s disease
Objective: To determine the presence, severity, functional impact and predisposing factors of motor complications. Background: Motor complications are well recognized in Parkinson’s disease (PD), but…NLX-112 has favorable safety and tolerability and displays efficacy against levodopa-induced dyskinesia (LID) in Parkinson’s disease (PD)
Objective: To assess the safety, tolerability and preliminary efficacy of NLX-112 (a.k.a. befiradol) in patients with moderate to severe LID in PD: a randomized, double-blind,…Genetic diagnosis of parkinsonian phenotype of Machado Joseph Diseasep (SCA-3) presenting with dopa induced dyskinesia
Objective: We report a rare type IV parkinsonian phenotype of MJD having a rare genetic mutation. SCA type 3 (SCA3), also known as Machado-Joseph disease…Demographic, clinical and genetic factors affecting amantadine response among patients with Parkinson disease
Objective: To identify factors that correlate with efficacy and tolerability of amantadine to predict therapeutic outcomes Background: Amantadine is the only commercially available medication to…The role of genetic factors in the occurrence of levodopa-induced motor complications in Parkinson’s disease
Objective: We aimed to evaluate the association of selected polymorphisms of COMT, DRD2, ANKK1, and DAT genes and the occurrence of levodopa-induced motor complications in…Levodopa-induced dyskinesia and Huntington’s chorea: link to current motor control theories
Objective: Determine if there is a motor control hypothesis that could explain movement kinematics of Huntington’s disease (HD) chorea and Parkinson’s disease (PD) levodopa-induced dyskinesia…Results from IRL790C005 – A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study Evaluating the Efficacy of Mesdopetam on Daily On-Time without Troublesome Dyskinesia in Patients with Parkinson’s Disease
Objective: The objective of the Phase 2b-trial was to investigate efficacy and safety of three doses of Mesdopetam as adjunct treatment in patients with PD…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 44
- Next Page »